Nonresponse to 18-month lamivudine monotheraphy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation

Journal of the Formosan Medical Association

Volumn 105, Issue 7, 2006, Pages 588-593

  Sheu, Ming Jen ^a   Lin, Ching Yih ^a   Sun, Chi Shu ^a   Kuo, Hsing Tao ^a   Koay, Lok Beng ^a   Lee, Chuan ^a   Chen, Jyh Jou ^a   Tang, Ling Yu ^a   Tsai, Sun Lung ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Acute exacerbation; Chronic hepatitis B; Dual genotype infection; Hepatitis B virus; Lamivudine therapy; Sustained response

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MONOTHERAPY; RELAPSE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS CARRIER; VIRUS MUTATION;

EID: 33746952075     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60155-8     Document Type: Article

References (33)

1. Lai CL, Chien RH, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
2. Jarvis B, Faulds D. Lamivudine: a review of its therapeutic potential in chronic hepatitis B. Drugs 1999;58:101-41.
3. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
4. Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.
5. Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
6. Doong SL, Tsai CH, Schinazi RF, et al. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-9.
7. Dienstag JL, Perillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
8. Mckenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-105.
9. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
10. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17.
11. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:1276-82.
12. Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003;39:S111-5.
13. Chien RN, Yeh CT, Tsai SL, et al. The determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-73.
14. Stuyver L, De Gendr S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000;81:67-74.
15. Arauz-Ruiz P, Norder H, Robertson BH, et al. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83:2059-73.
16. Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995;38:24-34.
17. Usuda S, Okamoto H, Iwanari H, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 1999;80:97-112.
18. Grandjacques C, Pradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000;33:430-9.
19. Chen BF, Chen PJ, Jow GM, et al. High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. J Med Virol 2004;74:536-42.
20. Chen BF, Kao JH, Liu CJ, et al. Genotypic dominance and novel recombinations in HBV genotype B and C coinfected intravenous drug users. J Med Virol 2004;73:13-22.
21. Perrillo R. Acute flares in chronic hepatitis B. the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;20:1009-22.
22. Tsai SL, Chen PJ, Lai MY, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J Clin Invest 1992;89:87-96.
23. Lindh M, Andersson AS, Gusdal A. Genotypes, nt1858 variants, and geographic origin of hepatitis B virus-largescale analysis using a new genotyping method. J Infect Dis 1997;175:1285-93.
24. Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988;69:2575-83.
25. Purcell RH. Hepatitis viruses: changing patterns of human disease. Proc Natl Acad Sci USA 1994;91:2401-5.
26. Kao JH, Chen PJ, Lai MY, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-9.
27. Sumi H, Yokosuka O, Seki S, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003;37:19-26.
28. Yuen MF, Sablon E, Yuan HJ, et al. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications and hepatocellular carcinoma. Hepatology 2003;37:562-7.
29. Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002.
30. Kao JH, Wu NH, Chen PJ, et al. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003;124:327-34.
31. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002;36:303-4.
32. Yuen MF, Wong DK, Sablon E, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003;8:531-4.
33. Kato H, Orito E, Gish RG, et al. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology 2002;35:922-9.